CStone Pharmaceuticals announces the joint development of loratinib with Pfizer in ROS1-positive advanced lung cancer, further deepening of strategic cooperation between the two parties

(Suzhou, China, June 15, 2021) CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focused on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs, announced that it will cooperate with Pfizer in The Greater China region has carried out collaborative research on ROS1-positive advanced non-small cell lung cancer (NSCLC) and jointly developed lorlatinib
.

This upcoming clinical study of ROS1-positive lung cancer in China is the world's first key study of loratinib on this target

In recent years, the incidence of lung cancer in China has continued to increase
.

According to the latest global cancer burden data in 20201, there will be approximately 820,000 new lung cancer cases in China in 2020, and approximately 710,000 lung cancer deaths

Loratinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) with central nervous system penetration
.

With its stunning data in CROWN Study 2, loratinib has recently been approved by the U.

In clinical studies, loratinib has also shown preliminary efficacy and good safety for ROS1-positive advanced NSCLC
.

In a phase I/II study, loratinib improved the objective response rate (ORR) and intracranial ORR in patients with ROS1-positive advanced NSCLC who were initially treated with TKI drugs or failed ROS1 inhibitor treatment

Dr.
Jiang Ningjun, Chairman and CEO of CStone Pharmaceuticals said:

"We are very happy to be able to jointly develop
loratinib
with Pfizer.

Loratinib is a new generation of ALK/ROS1 targeted drugs in Pfizer's global pipeline .
This further cooperation fully reflects Pfizer's strong clinical development capabilities for CStone Pharmaceuticals .

Pierre Gaudreault, President of Pfizer Biopharmaceutical Group China, said:

"Pfizer has long been committed to'bringing breakthrough innovations that will change their lives to patients' and is always proud of it
.

This deepening cooperation with CStone Pharmaceuticals allows us to add another step to this journey

Last year, CStone Pharmaceuticals and Pfizer reached a strategic cooperation, including Pfizer’s US$200 million equity investment in CStone Pharmaceuticals, CStone’s authorization of Pfizer to develop and commercialize suggliumab in mainland China, and CStone Pharmaceuticals Introduce more oncology products into the framework of cooperation with Pfizer in the Greater China region
.

CStone Pharmaceuticals and Pfizer will jointly select oncology products in the Pfizer pipeline that are in the late stage of research and development (that have passed the proof-of-concept) and jointly develop them in the Greater China region.

Following the joint development of loratinib, CStone and Pfizer will continue to promote diversified cooperation in the future to bring more innovative tumor therapies to cancer patients in China